Johns Hopkins University's Wilmer Eye Institute, with which Bayer holds a joint research and development collaboration focused on developing new ophthalmic therapies.
Versant Ventures, where Bayer invests in a venture capital fund to advance early medical innovation and patient care.
Ad Statistics
Times Displayed: 112999
Times Visited: 6736 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
"An important goal of Bayer in the U.S. is to build productive and sustainable partnerships to advance new treatments that improve the lives of patients," said Habib Dable, president of Bayer's U.S. pharmaceuticals division. "We want to be a partner of choice in the industry – one that collaborates effectively with not only scientists from the great research hubs in the U.S., but also clinicians, patient advocates and other key players essential to bringing novel medicines to market."
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.us.
Bayer® and the Bayer Cross® are registered trademarks of Bayer.
Forward-Looking Statements
This news release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
SOURCE Bayer
Back to HCB News
